Mar. Drugs 2014, 12(3), 1512-1529; doi:10.3390/md12031512
Article

Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice

email, email, email, email, email, email, email, email, email, email, email, email and * email
Received: 27 December 2013; in revised form: 19 February 2014 / Accepted: 24 February 2014 / Published: 13 March 2014
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: To determine whether cholera toxin B subunit and active peptide from shark liver (CTB-APSL) fusion protein plays a role in treatment of type 2 diabetic mice, the CTB-APSL gene was cloned and expressed in silkworm (Bombyx mori) baculovirus expression vector system (BEVS), then the fusion protein was orally administrated at a dose of 100 mg/kg for five weeks in diabetic mice. The results demonstrated that the oral administration of CTB-APSL fusion protein can effectively reduce the levels of both fasting blood glucose (FBG) and glycosylated hemoglobin (GHb), promote insulin secretion and improve insulin resistance, significantly improve lipid metabolism, reduce triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) levels and increase high density lipoprotein (HDL) levels, as well as effectively improve the inflammatory response of type 2 diabetic mice through the reduction of the levels of inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). Histopathology shows that the fusion protein can significantly repair damaged pancreatic tissue in type 2 diabetic mice, significantly improve hepatic steatosis and hepatic cell cloudy swelling, reduce the content of lipid droplets in type 2 diabetic mice, effectively inhibit renal interstitial inflammatory cells invasion and improve renal tubular epithelial cell nucleus pyknosis, thus providing an experimental basis for the development of a new type of oral therapy for type 2 diabetes.
Keywords: active peptide from shark liver; cholera toxin B subunit; Bombyx mori pupae; type 2 diabetes mellitus; oral administration
PDF Full-text Download PDF Full-Text [1273 KB, uploaded 13 March 2014 10:35 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Liu, Y.; Gao, Z.; Guo, Q.; Wang, T.; Lu, C.; Chen, Y.; Sheng, Q.; Chen, J.; Nie, Z.; Zhang, Y.; Wu, W.; Lv, Z.; Shu, J. Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice. Mar. Drugs 2014, 12, 1512-1529.

AMA Style

Liu Y, Gao Z, Guo Q, Wang T, Lu C, Chen Y, Sheng Q, Chen J, Nie Z, Zhang Y, Wu W, Lv Z, Shu J. Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice. Marine Drugs. 2014; 12(3):1512-1529.

Chicago/Turabian Style

Liu, Yunlong; Gao, Zhangzhao; Guo, Qingtuo; Wang, Tao; Lu, Conger; Chen, Ying; Sheng, Qing; Chen, Jian; Nie, Zuoming; Zhang, Yaozhou; Wu, Wutong; Lv, Zhengbing; Shu, Jianhong. 2014. "Anti-Diabetic Effects of CTB-APSL Fusion Protein in Type 2 Diabetic Mice." Mar. Drugs 12, no. 3: 1512-1529.

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert